ClinicalTrials.gg
RecruitingNCT07610122Updated Nov 4, 2026

Validation of the Turkish Version of the S3-NIV Questionnaire

An observational study in Respiratory Insufficiency and Chronic Respiratory Failure, sponsored by Istanbul Saglik Bilimleri University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Istanbul Saglik Bilimleri University · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 51 studies in Respiratory Insufficiency with a site in Turkey — 10 open to participants now, 10 under way, none of them phase 3. Respiratory Insufficiency · Turkey.

Planned enrollment
11th of 25
120 · median 108
Started
2026
with 4 others
Observational
25 of 51
6 open now
Registered
47th of 51
by date

Among the 51 studies in Respiratory Insufficiency with a site in Turkey, this one is the 11th largest by planned enrollment of the 25 observational ones that give a count, is one of 5 that started in 2026, is one of 25 observational ones, and was the 47th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

10 of the 51 studies in Respiratory Insufficiency with a site in Turkey are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Respiratory Insufficiency with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to evaluate the psychometric properties, including reliability and validity, of the Turkish version of the Severe Respiratory Insufficiency Questionnaire for Non-Invasive Ventilation (S3-NIV). The S3-NIV is a specific tool designed to assess difficulties and compliance in patients receiving home non-invasive ventilation. A total of 120 stable patients using home NIV for at least 3 months will be enrolled across multiple centers.

Read the detailed description

Following the official linguistic validation process authorized by the Mapi Research Trust, this multi-center observational study will assess the psychometric validity of the Turkish S3-NIV questionnaire. Patients will complete the 11-item S3-NIV questionnaire alongside a sociodemographic and clinical data form. To evaluate test-retest reliability, a randomly selected subgroup of patients (n=40) will re-complete the questionnaire 14 to 15 days after the initial administration. Internal consistency, construct validity (via factor analysis), and criterion validity (correlations with clinical parameters such as daily NIV usage hours and blood gas values) will be analyzed.

03

Conditions studied

  • Respiratory Insufficiency
  • Chronic Respiratory Failure

Keywords

  • Non-Invasive Ventilation
  • Validation
  • Questionnaire
  • Reliability
  • S3-NIV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with chronic respiratory failure who are followed up in the outpatient clinic and have been using a home non-invasive ventilation (NIV) device for at least 3 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with chronic respiratory failure requiring home non-invasive ventilation (NIV).
  • Using a home NIV device for at least 3 months.
  • Being in a clinically stable phase (no exacerbation or hospitalization in the last 1 month).
  • Able to understand and answer the questionnaire.
  • Provided written .

Exclusion criteria

Exclusion Criteria:

  • Acute respiratory failure or clinical instability.
  • Severe cognitive impairment or psychiatric disorders preventing reliable communication.
  • Active or terminal illness with a short .
  • Refusal to provide .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Home NIV Patients

    Patients with chronic respiratory failure who have been using home non-invasive ventilation (NIV) for at least 3 months and are in a clinically stable phase.

    Other: Turkish Version of the S3-NIV Questionnaire

Interventions

  • OtherTurkish Version of the S3-NIV Questionnaire

    An 11-item self-administered questionnaire designed to evaluate the difficulties and compliance of patients using home non-invasive ventilation (NIV).

06

What researchers measure

Primary outcomes

  1. Internal Consistency and Construct Validity of the Turkish S3-NIV

    Evaluated using Cronbach's alpha coefficient for internal consistency and Confirmatory/Exploratory Factor Analysis (CFA/EFA) to confirm the structural validity of the 11-item scale.

    Time frame: Baseline (Day 0)

Secondary outcomes

  1. Test-Retest Reliability

    Evaluated using the Intraclass Correlation Coefficient (ICC) between the first and second administrations of the questionnaire in a randomly selected subgroup.

    Time frame: 14 to 15 days after baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — A decision on sharing individual participant data (IPD) has not yet been made. Data sharing may be considered upon reasonable request to the principal investigator after the publication of the study results.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 13 months is below that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Jun 2027 and completion Dec 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 27, 2026
StartActual
May 21, 2026
Primary completionEst.
Jun 30, 2027was Oct 2026
CompletionEst.
Aug 31, 2027was Dec 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital is now Recruiting
Nov 4, 2026
Primary completion
Oct 30, 2026→Jun 30, 2027
Nov 4, 2026
Study completion
Dec 30, 2026→Aug 31, 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital is now Recruiting
    Primary completion Oct 30, 2026→Jun 30, 2027
    Study completion Dec 30, 2026→Aug 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07610122
Lead sponsor
Istanbul Saglik Bilimleri University
Responsible party
Dilek Unsal (Physiotherapist, PhD (c), Istanbul Saglik Bilimleri University) — Principal investigator
First posted
May 27, 2026
Start date
May 21, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Dilek Unsal, PT PhD(c)
Contact
fztdlkunsal@gmail.com
+90 530 4641198
Ipek Ozmen, Prof.
principal investigator · Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion